Has Tanya Dolson received payments from drug or device companies?

Yes. Drug and device makers reported $5,284 in general payments to Tanya Dolson across 181 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tanya Dolson did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tanya Dolson come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tanya Dolson

Family · Lodi, CANPI 1336835040

Payments from drug & device makers

$5,284in general payments, 2019–2025

Across 181 payments — averaging $29.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$523
Astellas Pharma US Inc$366
Novartis$290
Lilly USA, LLC$288
AstraZeneca$273
Pfizer$272
plus $3K from 50 others

What the payments were for

Food & beverage$4,39283%
Education$89217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	14	$523
Astellas Pharma US Inc	7	$366
Novartis	14	$290
Lilly USA, LLC	10	$288
AstraZeneca(2 entities)	9	$273
Pfizer	12	$272
AbbVie	8	$225
Incyte Corporation	5	$196
Daiichi Sankyo Inc.	4	$181
Regeneron Healthcare Solutions, Inc.	7	$171
Sanofi-aventis U.S. LLC	2	$168
E.r. Squibb & Sons, L.L.C.	7	$151
Sobi, Inc	2	$130
Exelixis Inc.	4	$129
Myriad Genetic Laboratories, Inc.	1	$112
Beigene USA, Inc.	5	$104
Bristol Myers Squibb	5	$103
Takeda Pharmaceuticals U.S.A., Inc.	3	$101
Gilead	1	$92
Eisai Inc.	3	$87
Merck	4	$81
GSK	3	$67
Sanofi	2	$65
Jazz Pharmaceuticals Inc.	2	$64
Genentech USA, Inc.	3	$64
Array Biopharma Inc	2	$59
EMD Serono, Inc.	3	$58
Springworks Therapeutics, Inc.	3	$55
Seagen Inc.	2	$53
Tersera Therapeutics LLC	2	$49
Bayer	2	$45
Aadi Bioscience, Inc.	3	$42
Beone Medicines USA, Inc.	2	$41
Amgen	2	$39
Pharmaessentia USA Corporation	2	$38
Stemline Therapeutics Inc.	1	$33
Blueprint Medicines Corporation	1	$32
Sumitomo Pharma America, Inc.	1	$31
Genmab U.S., Inc.	1	$31
Acrotech Biopharma Inc.	1	$31
Biocon Biologics Inc	1	$29
Puma Biotechnology, Inc.	1	$28
Sun Pharmaceutical Industries Inc.	1	$27
Deciphera Pharmaceuticals Inc.	1	$24
Apellis Pharmaceuticals, Inc.	1	$23
Invivyd Inc	1	$23
Kyowa Kirin, Inc.	1	$23
Morphosys, US Inc.	1	$22
G1 Therapeutics, Inc.	1	$22
Boehringer Ingelheim	1	$22
Foundation Medicine, Inc.	1	$20
Spectrum Pharmaceuticals Inc.	1	$20
Agios Pharmaceuticals, Inc.	1	$19
Pharmacosmos Therapeutics Inc.	1	$17
Karyopharm Therapeutics Inc.	1	$15
Recordati_rare_diseases_inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,284 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	49	$28,752
XareltoRivaroxaban	14	$15,903
LoperamideLoperamide Hcl	27	$1,126
Letrozole	34	$697
Prochlorperazine Maleate	66	$652
Ondansetron OdtOndansetron	59	$612
Hydroxyurea	17	$506
Mirtazapine	27	$376
Anastrozole	16	$276
Levothyroxine Sodium	22	$184
Prednisone	18	$86
Gabapentin	16	$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$272	$28,75249 claims
Johnson & JohnsonXarelto	$523	$15,90314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Lodi

Lori RobertsonChino Hills$475K
Annette ShonLos Angeles$406K
Nancy GardettoSan Diego$394K
Lisa HigginsHanford$311K
Jennifer TougasBakersfield$302K
Kim SchaferSacramento$288K
Dawn MeyerSan Diego$270K
Jennifer KangCerritos$255K
Jenine StoneEscondido$231K
Erin DwyerSan Diego$189K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →